xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
CLEVELAND, Feb. 01, 2016 -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 18th annual BIO CEO & Investor Conference to be held on February 8-9, 2016 in New York, NY, at The Waldorf Astoria New York.
Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Monday, February 8, 2016 at 2:00 p.m. EST in the Louis XVI Room.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies. Because its mission is to support industry-wide success, BIO presents a broad and unbiased view of investment opportunities and provides an annual forum for institutional investors, industry analysts, and senior biotechnology executives to shape the future investment landscape of the industry.
To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 90 days after the initial presentation.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
